Investigating how the MECOM gene affects high-risk leukemia
Functionally dissecting MECOM gene regulation in high-risk leukemia
This study is looking at how a gene called MECOM affects acute myeloid leukemia (AML) to help find better treatments for patients with this challenging type of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11221397 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the MECOM gene in acute myeloid leukemia (AML), a type of cancer with a poor prognosis. By creating a specialized cell-line model, researchers can control the degradation of MECOM to observe its effects on gene expression and cell behavior. The study aims to uncover the mechanisms by which MECOM influences leukemia development and how this knowledge could lead to improved treatments for patients with high-risk forms of AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with high-risk genetic profiles.
Not a fit: Patients with low-risk forms of leukemia or those not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with high-risk leukemia.
How similar studies have performed: Previous research has shown promise in targeting gene regulation in leukemia, suggesting that this approach could yield significant insights.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Fleming, Travis J — Harvard Medical School
- Study coordinator: Fleming, Travis J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.